Latest Sirolimus Stories
Scientists have discovered a drug they believe can reverse the effects of premature aging and could extend human life by over a decade.
DURHAM, N.C., June 29, 2011 /PRNewswire/ -- Micell Technologies, Inc.
NEW BRUNSWICK, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that it expects to record an after-tax restructuring charge in the range of $500-$600 million in the second quarter of 2011 as a result of restructuring plans announced by its subsidiary, Cordis Corporation.
BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO(TM) Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists.
PARIS, May 19, 2011 /PRNewswire/ -- OrbusNeich announced that data from multiple clinical trials supporting the safety and efficacy of the Genous Stent in cases where prolonged dual antiplatelet therapy (DAPT) is not advisable were featured today during the HEALING Symposium titled "How to assess and treat patients who are not suitable candidates for prolonged dual antiplatelet therapy" at EuroPCR 2011 in Paris. Presenters discussed current treatment alternatives to drug eluting stents (DES)...
HONG KONG, May 12, 2011 /PRNewswire/ -- OrbusNeich today announced that data from multiple studies of the Genous Stent will be presented at EuroPCR 2011 in Paris.
DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Micell Technologies, Inc.
EAST HANOVER, N.J., May 5, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved AfinitorÂ® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4).
A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma.
EAST HANOVER, N.J., April 12, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of AfinitorÂ® (everolimus) tablets for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin. The recommendation was provided after presentation of data from the everolimus RADIANT (RAD001 In Advanced Neuroendocrine Tumors) trial...